Literature DB >> 11339974

Therapeutic modulation of transcription factor activity.

J G Emery1, E H Ohlstein, M Jaye.   

Abstract

Aberrant gene expression is a fundamental cause of many disease-associated pathophysiologies. The pharmacological modulation of transcription factor activity therefore represents an attractive therapeutic approach to such disorders. With the exception of nuclear receptors, which are the direct targets of pharmaceuticals, other known classes of transcription factors are largely regulated indirectly by drugs that impact upon those signal transduction cascades that alter transcription factor phosphorylation and dephosphorylation and/or nuclear import. However, recent advances in drug discovery technologies now enable high-throughput screens that can identify molecules that act directly at the level of transcription factor complexes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11339974     DOI: 10.1016/s0165-6147(00)01661-8

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  8 in total

Review 1.  Transcription factor AP-2 and monoaminergic functions in the central nervous system.

Authors:  M Damberg
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

2.  ZNF384: A Potential Therapeutic Target for Psoriasis and Alzheimer's Disease Through Inflammation and Metabolism.

Authors:  Shougang Liu; Xiuqing Yuan; Hang Su; Fanghua Liu; Zhe Zhuang; Yongfeng Chen
Journal:  Front Immunol       Date:  2022-05-20       Impact factor: 8.786

3.  Effect of cholecystokinin octapeptide on tumor necrosis factor alpha transcription and nuclear factor-kappaB activity induced by lipopolysaccharide in rat pulmonary interstitial macrophages.

Authors:  Bin Cong; Shu-Jin Li; Yu-Xia Yao; Gui-Jun Zhu; Yi-Ling Ling
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

4.  Transcription factor decoy oligonucleotides modified with locked nucleic acids: an in vitro study to reconcile biostability with binding affinity.

Authors:  Rita Crinelli; Marzia Bianchi; Lucia Gentilini; Linda Palma; Mads D Sørensen; Torsten Bryld; Ravindra B Babu; Khalil Arar; Jesper Wengel; Mauro Magnani
Journal:  Nucleic Acids Res       Date:  2004-03-29       Impact factor: 16.971

5.  Protective effect of carnosol on lung injury induced by intestinal ischemia/reperfusion.

Authors:  Xiao-Feng Tian; Ji-Hong Yao; Xue-Song Zhang; Shu-Sen Zheng; Xin-Hua Guo; Li-Ming Wang; Zhen-Zhen Wang; Ke-Xin Liu
Journal:  Surg Today       Date:  2010-08-26       Impact factor: 2.549

6.  Ginsenoside Rb1 attenuates intestinal ischemia-reperfusion- induced liver injury by inhibiting NF-kappaB activation.

Authors:  Jin Wang; Lifen Qiao; Yongsheng Li; Guangtian Yang
Journal:  Exp Mol Med       Date:  2008-12-31       Impact factor: 8.718

7.  Brainstem levels of transcription factor AP-2 in rat are changed after treatment with phenelzine, but not with citalopram.

Authors:  Cecilia Berggard; Mattias Damberg; Lars Oreland
Journal:  BMC Pharmacol       Date:  2005-01-21

8.  Protective effect of ginsenoside Rb1 against lung injury induced by intestinal ischemia-reperfusion in rats.

Authors:  Jin Wang; Lifen Qiao; Shusheng Li; Guangtian Yang
Journal:  Molecules       Date:  2013-01-17       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.